文献速递白血病

N端脑钠肽前体是急性髓系白血病强化化疗反应、早期死亡和总生存的预后标志物

N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia.
PubMed 文献 · Am J Hematol · 2023-01-01

该研究分析312例接受3+7方案诱导化疗的急性髓系白血病(AML)患者诊断时N端脑钠肽前体(NT-proBNP)水平,发现199例(63.8%)升高,中位NT-proBNP在完全缓解、未缓解和早期死亡组间差异显著(p=.002),多因素分析显示NT-proBNP、年龄和ELN-2009分类是诱导化疗后结局的独立预测因素。

要点

  • 诊断时NT-proBNP升高(>125 pg/ml)见于199/312例(63.8%)AML患者。
  • 完全缓解、未缓解和早期死亡组中位NT-proBNP分别为153.3、225.9和735.5 pg/ml(p=.002)。
  • NT-proBNP、年龄和ELN-2009分类是总生存的独立预后变量(p<.01)。

核心结论

  • NT-proBNP是AML患者诱导失败、早期死亡和总生存缩短风险的独立预后因素。

研究设计与样本

  • 分析312例AML患者诊断时NT-proBNP水平,中位年龄61岁(范围17-89岁),接受3+7方案诱导化疗及最多4个周期中/高剂量阿糖胞苷巩固治疗。

主要发现

  • NT-proBNP升高(>125 pg/ml)199例(63.8%),正常(0-125 pg/ml)113例(36.2%),高度升高(>2000 pg/ml)20例(6.4%)。
  • 完全缓解、未缓解和早期死亡患者的中位NT-proBNP分别为153.3、225.9和735.5 pg/ml(p=.002)。
  • 正常、中度升高和高度升高NT-proBNP组的总生存差异显著(p<.001),该差异见于全部患者和<60岁患者,但不见于≥60岁患者。
  • 多因素分析中NT-proBNP、年龄和ELN-2009分类是诱导化疗后结局的独立预测因素。
  • 多因素分析中NT-proBNP、年龄和ELN-2009分类仍是总生存的独立预后变量(p<.01)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patient-related factors are of prognostic importance in acute myeloid leukemia (AML). Likewise, cardiac disorders may limit the tolerance of intensive therapy. Little is known about the prognostic value of N-terminal pro-brain natriuretic peptide (NT-proBNP). We analyzed NT-proBNP levels at diagnosis in 312 AML patients (median age: 61 years; range 17-89 years) treated with 3 + 7-based induction-chemotherapy and consolidation with up to four cycles of intermediate or high-dose ARA-C. NT-proBNP levels were elevated in 199 patients (63.8%), normal (0-125 pg/ml) in 113 (36.2%), and highly elevated (>2000 pg/ml) in 20 patients (6.4%). Median NT-proBNP levels differed significantly among patients with complete remission (153.3 pg/ml), no remission (225.9 pg/ml), or early death (735.5 pg/ml) (p = .002). In multivariate analysis, NT-proBNP, age, and the 2009 European LeukemiaNet (ELN-2009) classification were independent predictors of outcome after induction chemotherapy. Overall survival (OS) differed significantly between patients with normal, moderately elevated, and highly elevated NT-proBNP (p < .001). These differences were observed in all patients and in patients <60 years but not in those ≥60 years. In multivariate analysis, NT-proBNP, age, and ELN-2009 remained independent prognostic variables for OS (p < .01). Together, NT-proBNP is an independent prognostic factor indicating the risk of induction failure, early death, and reduced OS in patients with AML.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Graf I, Greiner G, Marculescu R, et al. N-terminal pro-brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia. Am J Hematol. 2023. PMID: 36588398. doi:10.1002/ajh.26805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。